The archive · Space, Robots, Defence · Strategic decision · 2021–2026
Varda returns the first commercial space-drug cargo to Earth, raises $329M
Varda bets drug crystals form better in microgravity: W-1 grew ritonavir in orbit and landed in Utah in 2024; about $329M raised and multiple returns by 2025.
Varda Space Industries
What the business is
Designing, building and operating autonomous spacecraft that manufacture pharmaceutical products in microgravity and return them to Earth in reentry capsules.
Starting capital：$90M Series B led by Caffeinated Capital (April 2024); $187M Series C (July 2025) brought total raised to about $329M
How it started
Founded in January 2021 by Will Bruey and Delian Asparouhov, Varda bet that cheaper launch would make low Earth orbit a manufacturing location. It ordered custom spacecraft from Rocket Lab and chose drug crystallization as its first commercial wedge.
What happened
W-1 launched in mid-2023 and grew crystals of ritonavir, an HIV antiviral, in a 27-hour experiment. The capsule waited months after the FAA denied an early reentry request, but landed at the Utah Test and Training Range on Feb 21, 2024 — the first commercial spacecraft to land on U.S. soil and the first space-manufacturing mission outside the ISS. A $90M Series B followed in April 2024. W-2 launched Jan 14, 2025 and landed in South Australia on Feb 28, the first commercial spacecraft to touch down in Australia.
How it ended up
A $187M Series C in July 2025 brought total capital to about $329M, funding new pharmaceutical labs in El Segundo and an office in Huntsville, Alabama. By mid-2025 the company said it had completed three launch-and-return missions, with a fourth vehicle (W-4) in orbit under the FAA's first-ever reentry vehicle operator license. The manufacture-and-return loop is proven, though drug revenue is still pre-commercial.
Background
Varda Space Industries, founded in January 2021 by Will Bruey and Delian Asparouhov, is building the first commercial service for manufacturing products in space: autonomous spacecraft that grow pharmaceutical crystals in microgravity, then return them to Earth in reentry capsules.
Its bet is that drug crystals form better without gravity — cleaner, more perfect structures that can improve formulations of existing drugs — and that the missing piece was commercial infrastructure, not science. W-1 launched in mid-2023, grew crystals of the HIV antiviral ritonavir, then waited through months of FAA reentry review before landing in Utah on Feb 21, 2024, the first commercial spacecraft to touch down on U.S. soil.
The demonstration unlocked capital: a $90M Series B in April 2024 and a $187M Series C in July 2025, about $329M total. W-2 launched Jan 14, 2025 and landed in South Australia on Feb 28, the first commercial spacecraft to land in Australia, carrying an expanded bioreactor plus hypersonic-test payloads for the Air Force Research Laboratory and NASA.
Customers so far include government researchers flying reentry and thermal-protection payloads, while the pharmaceutical revenue the bet depends on is still forming. The bet remains commercially unproven, but the full loop — manufacture in orbit, return, recover — is now a repeatable operation.
What has to be true
- ISS research had already shown microgravity improves drug crystals, so the unmet need was a return vehicle, not basic science.
- Buying Rocket Lab spacecraft let Varda skip building a satellite from scratch and concentrate on reentry and the manufacturing payload.
- Each successful return — Utah in 2024, Australia in 2025 — built the regulatory and operational track record pharma partners require.
- Government hypersonic-test payloads paid for early flights while pharmaceutical revenue was still forming.
What can be applied
When a market hinges on an unproven regulatory path, the first mover's real asset is the permission loop: the landing and licensing track record every future competitor must also build.
Aftermath
As of September 2026, Varda has returned multiple W-series capsules to Earth and launched W-4 under the FAA's first reentry-vehicle operator license, with an in-house satellite bus and heatshield replacing the original Rocket Lab hardware. The $187M Series C funds a 10,000 sq ft crystallization laboratory in El Segundo and a faster mission cadence, plus an office in Huntsville, Alabama. Revenue so far comes mainly from government reentry-testing partners such as AFRL and NASA. The core bet — that pharmaceutical companies will pay for in-space processing — is still unproven commercially.
Sources
- Rocket Lab Successfully Returns Spacecraft Capsule to Earth, Brings Back Pharmaceuticals Made in Space
- Varda Announces $90 million Series B Funding to Build Factories in Space
- Varda Space capsule lands in Australia with critical data for hypersonic vehicles
- Varda Space Industries' Series C Fundraiser reaches $187 Million for Medicine Creation in Space
spotted an error? The archive wants to know.
Your turn
You just read one. Describe what you are building, and see who is betting on the same thing.
Free account · 3 free questions · no card